Treatment of EOC cells with the anti-IL6 antibody (Ab) siltuximab has been shown to reduce constitutive cyto/chemokine production and inhibit IL6 signaling, tumor growth, the tumor-associated macrophage infiltrate, and angiogenesis in IL6–producing intraperitoneal ovarian cancer xenografts [13]. This evidence concerns the gene IL6 and ovarian carcinoma.